Ernexa Therapeutics Inc (ERNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Sales | 51 | 0 | 0 | 0 | 0 |
| Cost of Goods | 120 | 0 | 50 | N/A | N/A |
| Gross Profit | -69 | 0 | -50 | N/A | N/A |
| Operating Expenses | 5,556 | 4,549 | 5,316 | 4,737 | 8,304 |
| Operating Income | -5,505 | -4,549 | -5,316 | -4,737 | -8,304 |
| Interest Expense | 113 | -24 | -1 | 0 | 0 |
| Other Income | 19 | 21 | -96 | 287 | 993 |
| Pre-tax Income | -5,599 | -4,504 | -5,411 | -4,450 | -7,311 |
| Income Tax | -8 | 4 | -5 | 40 | 5 |
| Net Income Continuous | -5,591 | -4,508 | -5,406 | -4,490 | -7,316 |
| Net Income | $-5,591 | $-4,508 | $-5,416 | $-4,490 | $-7,316 |
| EPS Basic Total Ops | -386.06 | -318.59 | -397.30 | -341.08 | -933.28 |
| EPS Basic Continuous Ops | -387.35 | -318.62 | -395.21 | -343.27 | -932.38 |
| EPS Diluted Total Ops | -386.06 | -318.59 | -397.30 | -341.08 | -933.28 |
| EPS Diluted Continuous Ops | -387.35 | -318.62 | -395.21 | -343.27 | -932.38 |
| EBITDA(a) | $-4,936 | $-4,486 | $-5,254 | $-4,651 | $-8,183 |